Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies.
Ulf Martin GeisenMelike SümbülFlorian TranHayley M ReidLena VullriedeMaria CiripoiAnn C LongardtPaula HoffPeter J MorrisonVerena E SchneiderRainald ZeunerJan H SchirmerAndrea SteinbachSusanna NikolausS GerdesStefan SchreiberPetra BacherBimba Franziska HoyerPublished in: RMD open (2021)
Although the long-term efficacy of SARS-CoV2 vaccination in CID patients undergoing disease-modifying therapy is still not known, the pronounced declines in humoral responses towards SARS-CoV2 6 months after mRNA vaccination in the context of TNF blockade should be considered when formulating booster regimens. These patients should be considered for early booster vaccinations.